AMRN Amarin Corporation plc

15.15
+0.71  (+5%)
Previous Close 14.44
Open 14.63
Price To Book 42.08
Market Cap 5,411,799,342
Shares 357,214,478
Volume 7,237,988
Short Ratio
Av. Daily Volume 9,247,638

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Advisory Committee meeting November 14, 2019. PDUFA date under priority review September 28, 2019 but will be extended, potentially to December 28, 2019 (unconfirmed).
Vascepa
High Triglycerides With Mixed Dyslipidemia

Latest News

  1. Better Buy: GW Pharmaceuticals vs. Amarin
  2. Another Day, Another Buy Rating for Amarin (AMRN) Stock
  3. Amarin Shares Show Heart as Anti-Cholesterol Drug Firm Bucks Market Rout
  4. Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
  5. Don’t Say Bye Bye to Amarin (AMRN) Stock, Say Buy Buy
  6. Amarin Stock Crashes as FDA Plans Panel Review
  7. Pharma companies Amarin, Nektar Therapeutics nosedive on product concerns
  8. How the 10 Best Stocks From Last Year Hold Up Today
  9. Why Amarin Stock Is Tanking Today
  10. Drugmakers Put Bad Spin on a Bizarre Week
  11. Biotech Investors Jolted Out of Summer Lull as High-Fliers Sink
  12. Amarin Shares Topple On Adcom Meeting Surprise For Fish Oil Pill
  13. Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm
  14. The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2
  15. [video]Amarin Dives on Surprise FDA Heart-Drug Review
  16. Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA
  17. Biotech Stocks to Watch Through the 2nd Half of 2019
  18. Edited Transcript of AMRN earnings conference call or presentation 31-Jul-19 11:30am GMT
  19. Amarin’s Q2 Earnings and Robust 2019 Outlook
  20. What You'll Want to Know About Amarin's Strong Q2 Results